查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球 T 細胞治療市場評估：按方式、治療類型、適應症、最終用戶、地區、機會、預測（2016-2030）
市場調查報告書
商品編碼
1355048

全球 T 細胞治療市場評估：按方式、治療類型、適應症、最終用戶、地區、機會、預測（2016-2030）

T-Cells therapy Market Assessment, By Modality, By Therapy Type, By Indication, By End-user, By Region, Opportunities and Forecast, 2016-2030F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

全球T細胞治療市場規模預計將從2022年的33.3億美元增加到2030年的129.8億美元，2023-2030年預測期間複合年增長率為18.54%。

增加政府和私人戰略投資

Tecartus、Yescarta 和 Kymriah 獲得批准後，一些組織將其商業模式從小規模化療和基於蛋白質的療法開發轉變為工程療法。這一因素正在推動私人和公共機構的策略性投資並促進市場成長。由於產品核准的增加和生產能力的提高，預計未來幾年 T 細胞治療實體的市場競爭將會擴大。

例如，2022 年 2 月，美國 FDA 批准了 Yescarta，這是第一個用於治療復發或難治性大 B 細胞淋巴瘤 (LBCL) 的嵌合抗原受體 (CAR) T 細胞療法。Yescarta 獲得 NCCN 治療指南 1 類推薦，是第一個獲得此殊榮的 CAR-T 細胞療法。同樣，2022年2月，FDA宣布siltakabutagene autoleucel（siltakabutagene autoreucel Carvykti）獲得批准。

2023 年 1 月，California Institute for Regenerative Medicine（CIRM）承諾投入 400 萬美元來開發和測試 CAR-T 細胞療法，以治療多種 B 細胞惡性腫瘤，包括淋巴瘤和白血病。

CAR-T細胞療法的進展

在 CAR-T 細胞療法中，從患者身上收集的 T 細胞經過人工生物工程改造以表達 CAR。CAR-T細胞領域的公司正在尋求與其他公司的策略聯盟，包括聯盟、業務擴張、協議、聯合研究和新產品推出，這些正在推動T細胞治療市場的成長。

例如，Janssen Biotech, Inc.生產的CARVYKTI於2022年獲得FDA批准。嵌合抗原受體 T 細胞 (CAR-T) 是一種稱為 CARVYKTI 的療法的縮寫。患有多發性骨髓瘤（一種骨髓惡性腫瘤）的成年患者可以使用 CARVYKTI (Ciltakabutagene Autoleucel) 進行治療。CARVYKTI 治療在四次或多次先前治療後復發或變得難治的多發性骨髓瘤成年患者。該藥物由蛋白□體抑制劑、免疫調節劑和抗 CD38 單株抗體組成。

治療方法的最新進展

近年來，全球T細胞治療市場取得了顯著進展。CAR-T療法等創新技術正在徹底改變癌症治療，研究人員正在探索TCR療法等下一代T細胞療法，擴大可治療疾病的範圍。此外，源自健康捐贈者的同種異體 T 細胞療法的發展使治療變得更加容易。這些突破代表了個人化和現成 T 細胞療法的光明前景，擴大了全球市場治療選擇的範圍。

COVID-19 的影響

COVID-19的爆發阻礙了全球醫療產業的活動，特別是T細胞治療市場。由於大多數國家實施了封鎖政策，疫情對全球 T 細胞治療市場造成了打擊。供應鏈中斷導致一些公司 T 細胞療法的生產和供應延誤。這場大流行對多項 T 細胞療法臨床試驗造成了重大干擾，其中一些試驗被推遲或完全取消。

但值得注意的是，疫情發生後，癌症病患增多，醫療產業創新需求凸顯，不少企業加強研發。因此，鼓勵資助旨在了解如何應用 T 細胞療法治療病毒感染的研究。例如，Tevogen Bio 於 2022 年 11 月宣布打算探討 TVGN-489 的潛在治療用途，TVGN-489 是一種針對 COVID-19 的研究性 T 細胞療法。

本報告研究分析了全球T細胞治療市場，提供市場規模和預測、市場動態、主要參與者的現狀和前景等。

目錄

第一章研究方法論

第二章 專案範圍與定義

第三章 COVID-19對全球T細胞治療市場的影響

第 4 章執行摘要

第五章 全球T細胞治療市場展望（2016-2030）

  • 市場規模及預測
    • 金錢數額
  • 按方式
    • 研究
    • 商業化
  • 按治療類型
    • CAR-T細胞療法
    • 基於 T 細胞受體 (TCR)
    • 基於腫瘤浸潤淋巴細胞（TIL）
  • 按指示
    • 血液腫瘤
    • 實體腫瘤
    • 其他
  • 按最終用戶
    • 醫院
    • 癌症治療中心
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 市場佔有率：依公司劃分（2022 年）

第六章 全球 T 細胞治療市場展望：按地區（2016-2030）

  • 北美
    • 市場規模及預測
    • 按方式
    • 按治療類型
    • 按指示
    • 按最終用戶
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 意大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 南美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印度尼西亞
    • 菲律賓
  • 中東/非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 南非

第七章 市場測繪（2022）

  • 按組件
  • 按技術
  • 按最終用戶
  • 按產品
  • 按地區

第八章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析 - 數量和價值
  • 供應/價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第九章市場動態

  • 增長動力
  • 成長限制因素（問題、限制因素）

第十章 監理框架與創新

  • 臨床試驗
  • 專利態勢
  • 監管審批
  • 創新/新技術

第十一章 主要公司情況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名市場領導者的市場收入分析（2022 年）
  • 併購/合資（如適用）
  • SWOT分析（針對5家進入市場的公司）
  • 專利分析（如果適用）

第12章價格分析

第十三章案例研究

第十四章 主要公司展望

  • Novartis AG
  • Merck KGaA
  • Gilead Sciences Inc.
  • TCR2 Therapeutics Inc
  • Bluebird Bio Inc.
  • Sorrento Therapeutics
  • Fate Therapeutics
  • Pfizer Inc.
  • Amgen
  • Celgene Corporation

第十五章 戰略建議

第十六章 關於我們公司、免責聲明

Product Code: MX10500

Global T-Cells therapy market size was valued at USD 3.33 billion in 2022, and is expected to reach USD 12.98 billion in 2030, with a CAGR of 18.54% for the forecast period between 2023 and 2030F. The market for T-cell treatment is constantly evolving and expanding, largely due to ongoing research and development initiatives. To improve efficacy and widen the applications of T-cell therapies, scientists and researchers are constantly investigating new methods, tools, and therapeutic targets. The key factors driving the expansion of the T-cell therapy market size are the rise in cancer prevalence, elderly population, and the usage of various cell therapy technologies to treat cancer symptoms. The prevalence of certain cancers such as leukemia, myeloma, lymphoma, and cancer relapse increase the need for efficient therapeutic interventions and fuels market growth. Also, multiple medications that are currently in the clinical development stage are fueling the market's expansion. For instance, Caribou Biosciences, Inc.'s CB-010 and CB-011 are undergoing phase I clinical studies. Similarly, Cartesian Therapeutics, Inc.'s DESCARTES-17 and DESCARTES-25 are now undergoing preclinical and Phase I trials, respectively. Thus, it is further projected that key companies' attention to developments may possibly fuel the market for T-cell treatment growth.

Increased Strategic Government and Private Investments

After tecartus, Yescarta, and Kymriah were approved, several organizations changed their business models from developing small chemical and protein-based treatments to adoptive therapy. This element has encouraged strategic investments by both private and public organizations, which has helped the market grow. The market rivalry for T-cell therapy entities is anticipated to expand in the coming years due to increasing product approval and rising production capacities.

For instance, the U.S. FDA approved Yescarta, the first chimeric antigen receptor (CAR) T-cell treatment in February 2022 to manage relapsed or refractory large B-cell lymphoma (LBCL). The NCCN Treatment Guideline's Category 1 recommendation for Yescarta makes it the first CAR T-cell treatment to receive this distinction. The FDA similarly approved ciltacabtagene autoleucel (Carvykti) in February 2022 for patients with multiple myeloma that is refractory, which did not respond to treatment, or has reappeared after treatment (relapsed).

The California Institute for Regenerative Medicine (CIRM) committed $4 million in January 2023 to develop and test a CAR T-cell therapy for treating diverse B-cell malignancies, including lymphomas and leukemias.

Following the closure of the transaction in May 2023 , Laurus Labs' share in ImmunoACT will rise to 33.86% on a fully diluted basis. In November 2021, the corporation had already purchased 26.62% of ImmunoACT. The CAR T-cell therapy assets in ImmunoACT's portfolio are in various stages of development and are used to treat various cancers and autoimmune illnesses. With this funding, Laurus Labs is more committed to offering patients revolutionary Cell and Gene Therapy technology at an affordable price. This funding will aid ImmunoACT in preparing to produce more medications.

Advancement in CAR T-Cell Therapy

In CAR T-cell therapy, T-cells taken from patients are artificially bioengineered to express CARS, which can recognize and attach to the cancer cells. Companies in the CAR T-cell segment are engaging in strategic developments with other companies, such as partnerships, expansions, agreements, collaborations, and the introduction of new products, which is promoting the growth of the T-cell treatment market.

For instance, the FDA authorized CARVYKTI produced by Janssen Biotech, Inc. in 2022. Chimeric antigen receptor T-cell, or CAR-T, is the abbreviation for the therapy known as CARVYKTI. Adult patients with multiple myeloma, a bone marrow malignancy, can receive treatment with CARVYKTI (ciltacabtagene autoleucel). After four or more prior lines of therapy, CARVYKTI treats adult patients with multiple myeloma that have relapsed or become resistant to treatment. It comprises a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.

Astellas committed USD 50 million to Poseida's CAR T-cell therapy in August 2023. Astellas will have exclusive negotiating rights and first choice for licensing P-MUC1C-ALLO1 in solid tumors as part of the agreement.

Government Regulations

The development, testing, and marketing of cell therapies and other biologics used in T-cell therapy treatments, such as adoptive cell transfer (ACT), are governed by the U.S. Food and Drug Administration (FDA).

Cell therapy evaluation standards and guidelines have been published by the European Medicines Agency (EMA) for use in clinical and human trials.

The safety, effectiveness, and quality of biological products used in T-cell therapy treatments are overseen by the FDA's Center for Biologic Evaluation and Research (CBER).

Best practices have been established by the National Institutes of Health (NIH ) for carrying out clinical trials utilizing cell therapies, particularly for T-cell therapy. Guidelines for patient selection criteria, risk assessment techniques, and monitoring procedures are included.

To guarantee that cell therapies are produced safely and ethically, the International Society for Cellular Therapy (ISCT) offers rules and criteria.

Latest Advancements in Therapeutic Approaches

The global T-cell therapy market has witnessed significant advancements in recent years. Innovative technologies like CAR-T therapy have revolutionized cancer treatment, researchers are exploring next-generation T-cell therapies, such as TCR (T-cell Receptor) therapies, which broadens the scope of treatable diseases. Furthermore, the development of allogeneic T-cell therapies, derived from healthy donors, is making treatments more accessible. These breakthroughs signify a promising future for personalized and off-the-shelf T-cell therapies, expanding the horizon of therapeutic options in the global market.

The U.S. Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus Therapeutics plc, a clinical-stage biopharmaceutical firm, to its lead gene therapy obecabatagene autoleucel (obe-cel) in April 2022. In the ongoing FELIX Phase 2 study in adult relapsed/refractory B-Acute Lymphocytic Leukemia, a CD19-directed autologous chimeric antigen receptor (CAR) T treatment is being examined.

In 2022, Novartis International AG introduced a novel T-Cell Therapy known as Kymriah, specifically designed for addressing relapsed or refractory follicular lymphoma. This innovative therapy, classified as a CD19-targeted CAR-T-cell therapy, received FDA approval.

Impact of COVID-19

The COVID-19 outbreak hampered operations in the global health care industry, especially the T-cell treatment market. The pandemic hurt the global T-cell treatment market since most nations implemented lockdown policies. Due to supply chain interruptions, certain businesses encountered delays in producing and delivering T-cell therapies. The pandemic caused significant disruptions to several clinical trials of T-cell treatments, with some trials being postponed or discontinued entirely.

However, it was noted that post-pandemic, the prevalence of cancer cases has brought attention to the need for innovation in the healthcare industry, and many businesses are boosting their efforts in R&D. It has encouraged funding for research aimed at figuring out how T-cell treatments might be applied to treat viral infections. For instance, Tevogen Bio announced, in November 2022, it intended to examine the potential therapeutic uses of TVGN-489, an investigational COVID-19 T-cell therapy, in Long COVID. The highly purified cytotoxic CD8+ T lymphocytes (CTLs) TVGN-489 are designed to locate and eradicate SARS-CoV-2 infected cells.

Key Players Landscape and Outlook

The increasing number of businesses engaging in CAR-T therapy development is projected to boost market competition. Novartis AG and Kite Pharma currently dominate the T-cell therapy market through innovative and novel product introductions. In addition, numerous prominent corporations are launching significant initiatives to strengthen their market presence. For instance, in June 2022, Immunocore Ltd., a commercial-stage biotechnology startup, engaged into a clinical trial collaboration and supply deal with Sanofi. Sanofi can use KIMMTRAK to analyze their precisely PEGylated, tailored form of IL-2, SAR444245 in this collaboration. The agreement will help the company's expansion by improving cell therapy manufacturing operations.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on the Global T-Cells Therapy Market

4. Executive Summary

5. Global T-Cells Therapy Market Outlook, 2016-2030F

  • 5.1. Market Size & Forecast
    • 5.1.1 By Value
  • 5.2. By Modality
    • 5.2.1. Research
    • 5.2.2. Commercialized
  • 5.3. By Therapy Type
    • 5.3.1. CAR T-cell Therapy
    • 5.3.2. T-Cell Receptor (TCR)-based
    • 5.3.3. Tumor Infiltrating Lymphocytes (TIL)-based
  • 5.4. By Indication
    • 5.4.1. Hematologic Malignancies
      • 5.4.1.1. Lymphoma
      • 5.4.1.2. Leukemia
      • 5.4.1.3. Myeloma
    • 5.4.2. Solid Tumors
      • 5.4.2.1. Melanoma
      • 5.4.2.2. Brain & Central Nervous System
      • 5.4.2.3. Liver Cancer
      • 5.4.2.4. Others
    • 5.4.3. Others
  • 5.5. By End-user
    • 5.5.1. Hospitals
    • 5.5.2. Cancer Treatment Centers
  • 5.6. By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. South America
    • 5.6.5. Middle East & Africa
  • 5.7. By Company Market Share (%), 2022

6. Global T-Cells Therapy Market Outlook, By Region, 2016-2030F

  • 6.2. North America*
    • 6.2.1. Market Size & Forecast
      • 6.2.1.1. By Value
    • 6.2.2. By Modality
      • 6.2.2.1. Research
      • 6.2.2.2. Commercialized
    • 6.2.3. By Therapy Type
      • 6.2.3.1. CAR T-cell Therapy
      • 6.2.3.2. T-Cell Receptor (TCR)-based
      • 6.2.3.3. Tumor Infiltrating Lymphocytes (TIL)-based
    • 6.2.4. By Indication
      • 6.2.4.1. Hematologic Malignancies
      • 6.2.4.1.1. Lymphoma
      • 6.2.4.1.2. Leukemia
      • 6.2.4.1.3. Myeloma
      • 6.2.4.2. Solid Tumors
      • 6.2.4.2.1. Melanoma
      • 6.2.4.2.2. Brain & Central Nervous System
      • 6.2.4.2.3. Liver Cancer
      • 6.2.4.2.4. Others
    • 6.2.5. By End-user
      • 6.2.5.1. Hospitals
      • 6.2.5.2. Cancer Treatment Centers
    • 6.2.6. United States*
      • 6.2.6.1. Market Size & Forecast
      • 6.2.6.1.1. By Value
      • 6.2.6.2. By Therapy Type
      • 6.2.6.2.1. CAR T-cell Therapy
      • 6.2.6.2.2. T-Cell Receptor (TCR)-based
      • 6.2.6.2.3. Tumor Infiltrating Lymphocytes (TIL)-based
      • 6.2.6.3. By Indication
      • 6.2.6.3.1. Hematologic Malignancies
      • 6.2.6.3.1.1. Lymphoma
      • 6.2.6.3.1.2. Leukemia
      • 6.2.6.3.1.3. Myeloma
      • 6.2.6.3.2. Solid Tumors
      • 6.2.6.3.2.1. Melanoma
      • 6.2.6.3.2.2. Brain & Central Nervous System
      • 6.2.6.3.2.3. Liver Cancer
      • 6.2.6.3.2.4. Others
      • 6.2.6.4. By End-user
      • 6.2.6.4.1. Hospitals
      • 6.2.6.4.2. Cancer Treatment Centers
    • 6.2.7. Canada
    • 6.2.8. Mexico

All segments will be provided for all regions and countries covered:

  • 6.3. Europe
    • 6.3.1. Germany
    • 6.3.2. France
    • 6.3.3. Italy
    • 6.3.4. United Kingdom
    • 6.3.5. Russia
    • 6.3.6. Netherlands
    • 6.3.7. Spain
    • 6.3.8. Turkey
    • 6.3.9. Poland
  • 6.4. South America
    • 6.4.1. Brazil
    • 6.4.2. Mexico
    • 6.4.3. Argentina
  • 6.5. Asia-Pacific
    • 6.5.1. India
    • 6.5.2. China
    • 6.5.3. Japan
    • 6.5.4. Australia
    • 6.5.5. Vietnam
    • 6.5.6. South Korea
    • 6.5.7. Indonesia
    • 6.5.8. Philippines
  • 6.6. Middle East & Africa
    • 6.6.1. Saudi Arabia
    • 6.6.2. UAE
    • 6.6.3. South Africa

7. Market Mapping, 2022

  • 7.2. By Component
  • 7.3. By Technology
  • 7.4. By End-user
  • 7.5. By Product
  • 7.6. By Region

8. Macro Environment and Industry Structure

  • 8.2. Supply Demand Analysis
  • 8.3. Import Export Analysis - Volume and Value
  • 8.4. Supply/Value Chain Analysis
  • 8.5. PESTEL Analysis
    • 8.5.1. Political Factors
    • 8.5.2. Economic System
    • 8.5.3. Social Implications
    • 8.5.4. Technological Advancements
    • 8.5.5. Environmental Impacts
    • 8.5.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.6. Porter's Five Forces Analysis
    • 8.6.1. Supplier Power
    • 8.6.2. Buyer Power
    • 8.6.3. Substitution Threat
    • 8.6.4. Threat from New Entrant
    • 8.6.5. Competitive Rivalry

9. Market Dynamics

  • 9.2. Growth Drivers
  • 9.3. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.2. Clinical Trials
  • 10.3. Patent Landscape
  • 10.4. Regulatory Approvals
  • 10.5. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.2. Competition Matrix of Top Five Market Leaders
  • 11.3. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 11.4. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.5. SWOT Analysis (For Five Market Players)
  • 11.6. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.2. Novartis AG
    • 14.2.1. Company Details
    • 14.2.2. Key Management Personnel
    • 14.2.3. Products & Services
    • 14.2.4. Financials (As reported)
    • 14.2.5. Key Market Focus & Geographical Presence
    • 14.2.6. Recent Developments
  • 14.3. Merck KGaA
  • 14.4. Gilead Sciences Inc.
  • 14.5. TCR2 Therapeutics Inc
  • 14.6. Bluebird Bio Inc.
  • 14.7. Sorrento Therapeutics
  • 14.8. Fate Therapeutics
  • 14.9. Pfizer Inc.
  • 14.10. Amgen
  • 14.11. Celgene Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 2. Global T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 3. Global T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 4. Global T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 5. Global T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 6. Global T-Cells Therapy Market Share, By Region, In USD Billion, 2016-2030F
  • Figure 7. North America T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 8. North America T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 9. North America T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 10. North America T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 11. North America T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 12. North America T-Cells Therapy Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 13. United States T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 14. United States T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 15. United States T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 16. United States T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 17. United States T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 18. Canada T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 19. Canada T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 20. Canada T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 21. Canada T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 22. Canada T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 23. Mexico T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 24. Mexico T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 25. Mexico T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 26. Mexico T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 27. Mexico T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 28. Europe T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 29. Europe T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 30. Europe T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 31. Europe T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 32. Europe T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 33. Europe T-Cells Therapy Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 34. Germany T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 35. Germany T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 36. Germany T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 37. Germany T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 38. Germany T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 39. France T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 40. France T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 41. France T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 42. France T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 43. France T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 44. Italy T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 45. Italy T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 46. Italy T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 47. Italy T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 48. Italy T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 49. United Kingdom T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 50. United Kingdom T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 51. United Kingdom T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 52. United Kingdom T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 53. United Kingdom T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 54. Russia T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 55. Russia T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 56. Russia T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 57. Russia T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 58. Russia T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 59. Netherlands T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 60. Netherlands T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 61. Netherlands T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 62. Netherlands T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 63. Netherlands T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 64. Spain T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 65. Spain T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 66. Spain T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 67. Spain T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 68. Spain T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 69. Turkey T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 70. Turkey T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 71. Turkey T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 72. Turkey T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 73. Turkey T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 74. Poland T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 75. Poland T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 76. Poland T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 77. Poland T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 78. Poland T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 79. South America T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 80. South America T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 81. South America T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 82. South America T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 83. South America T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 84. South America T-Cells Therapy Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 85. Brazil T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 86. Brazil T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 87. Brazil T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 88. Brazil T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 89. Brazil T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 90. Argentina T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 91. Argentina T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 92. Argentina T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 93. Argentina T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 94. Argentina T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 95. Asia-Pacific T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 96. Asia-Pacific T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 97. Asia-Pacific T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 98. Asia-Pacific T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 99. Asia- Pacific Cream Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 100. Asia-Pacific T-Cells Therapy Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 101. India T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 102. India T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 103. India T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 104. India T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 105. India T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 106. China T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 107. China T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 108. China T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 109. China T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 110. China T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 111. Japan T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 112. Japan T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 113. Japan T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 114. Japan T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 115. Japan T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 116. Australia T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 117. Australia T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 118. Australia T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 119. Australia T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 120. Australia T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 121. Vietnam T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 122. Vietnam T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 123. Vietnam T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 124. Vietnam T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 125. Vietnam T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 126. South Korea T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 127. South Korea T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 128. South Korea T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 129. South Korea T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 130. South Korea T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 131. Indonesia T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 132. Indonesia T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 133. Indonesia T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 134. Indonesia T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 135. Indonesia T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 136. Philippines T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 137. Philippines T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 138. Philippines T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 139. Philippines T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 140. Philippines T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 141. Middle East & Africa T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 142. Middle East & Africa T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 143. Middle East & Africa T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 144. Middle East & Africa T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 145. Middle East & Africa T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 146. Middle East & Africa T-Cells Therapy Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 147. Saudi Arabia T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 148. Saudi Arabia T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 149. Saudi Arabia T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 150. Saudi Arabia T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 151. Saudi Arabia T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 152. UAE T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 153. UAE T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 154. UAE T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 155. UAE T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 156. UAE T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 157. South Africa T-Cells Therapy Market, By Value, In USD Billion, 2016-2030F
  • Figure 158. South Africa T-Cells Therapy Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 159. South Africa T-Cells Therapy Market Share, By Therapy Type, In USD Billion, 2016-2030F
  • Figure 160. South Africa T-Cells Therapy Market Share, By Indication, In USD Billion, 2016-2030F
  • Figure 161. South Africa T-Cells Therapy Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 162. By Modality Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 163. By Therapy Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 164. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 165. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022